These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 20545952)

  • 41. Clinical benefits in patients with psoriasis after efalizumab therapy: clinical trials versus practice.
    Ricardo RR; Rhoa M; Orenberg EK; Li N; Rundle AC; Caro I
    Cutis; 2004 Sep; 74(3):193-200. PubMed ID: 15499762
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Urticaria associated with hyper-IgE in a patient with psoriasis undergoing treatment with efalizumab.
    Saraceno R; Scotto G; Chiricozzi A; Chimenti S
    Acta Derm Venereol; 2009; 89(4):412-3. PubMed ID: 19688158
    [No Abstract]   [Full Text] [Related]  

  • 43. Profiling lymphocyte subpopulations in peripheral blood under efalizumab treatment of psoriasis by multi epitope ligand cartography (MELC) robot microscopy.
    Bonnekoh B; Malykh Y; Böckelmann R; Bartsch S; Pommer AJ; Gollnick H
    Eur J Dermatol; 2006; 16(6):623-35. PubMed ID: 17229602
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative immunophenotypic features of EBV-positive and EBV-negative atypical lymphocytosis.
    Hudnall SD; Patel J; Schwab H; Martinez J
    Cytometry B Clin Cytom; 2003 Sep; 55(1):22-8. PubMed ID: 12949956
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efalizumab treatment of psoriasis vulgaris: a cohort study in outpatient clinical practice.
    Puig L; Roé E; García-Navarro X; Corella F; Alomar A
    Clin Exp Dermatol; 2009 Jun; 34(4):469-75. PubMed ID: 19077105
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical management with efalizumab of a patient with psoriasis and comorbid vitiligo.
    Fernandez-Obregon AC
    J Drugs Dermatol; 2008 Jul; 7(7):679-81. PubMed ID: 18664161
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Successful treatment of hand and foot psoriasis with efalizumab therapy.
    Fretzin S; Crowley J; Jones L; Young M; Sobell J
    J Drugs Dermatol; 2006 Oct; 5(9):838-46. PubMed ID: 17039648
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.
    Leonardi CL; Papp KA; Gordon KB; Menter A; Feldman SR; Caro I; Walicke PA; Compton PG; Gottlieb AB;
    J Am Acad Dermatol; 2005 Mar; 52(3 Pt 1):425-33. PubMed ID: 15761420
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efalizumab-induced autoimmune pancytopenia.
    Tom WL; Miller MD; Hurley MY; Suneja T; Kudva G; Leonardi CL; Obadiah JM
    Br J Dermatol; 2006 Nov; 155(5):1045-7. PubMed ID: 17034539
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Severe erythroderma in a patient under intermittent therapy with efalizumab.
    Hernandez Garcia I
    J Drugs Dermatol; 2008 Oct; 7(10):987-9. PubMed ID: 19112767
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term efalizumab therapy for patients with moderate-to-severe, chronic plaque psoriasis: results from an Australian expanded access program.
    Foley P; Freeman M; Gebauer K; Murrell D; Shumack S; Tyson C; Varigos G
    Int J Dermatol; 2009 Dec; 48(12):1376-84. PubMed ID: 19930495
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Case reports: practical experience with efalizumab in hand and foot psoriasis.
    Cohen DJ; Scherschun L
    J Drugs Dermatol; 2007 Dec; 6(12):1224-30. PubMed ID: 18189064
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.
    Costanzo A; Talamonti M; Botti E; Spallone G; Papoutsaki M; Chimenti S
    Dermatology; 2009; 219(1):48-53. PubMed ID: 19372639
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Erythrodermic CD8+ pseudolymphoma during infliximab treatment in a patient with psoriasis: use of cyclosporine as a rescue therapy.
    Safa G; Luce K; Darrieux L; Tisseau L; Ortonne N
    J Am Acad Dermatol; 2014 Oct; 71(4):e149-50. PubMed ID: 25219741
    [No Abstract]   [Full Text] [Related]  

  • 55. Persistent CMV infection correlates with disease activity and dominates the phenotype of peripheral CD8+ T cells in psoriasis.
    Weitz M; Kiessling C; Friedrich M; Prösch S; Höflich C; Kern F; Volk HD; Sterry W; Asadullah K; Döcke WD
    Exp Dermatol; 2011 Jul; 20(7):561-7. PubMed ID: 21410770
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Delayed autoimmune hemolytic anemia in efalizumab-treated psoriasis.
    Kwan JM; Reese AM; Trafeli JP
    J Am Acad Dermatol; 2008 Jun; 58(6):1053-5. PubMed ID: 18328597
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Erythrodermic psoriasis successfully treated with efalizumab.
    Piccirillo F; Stinco G; Patrone P
    Eur J Dermatol; 2008; 18(3):357-8. PubMed ID: 18474483
    [No Abstract]   [Full Text] [Related]  

  • 58. Severe exacerbation of chronic plaque psoriasis following initially effective therapy with efalizumab: clinical characterization and therapeutic management.
    Ulmer A; Wölbing F; Metzler G; Schanz S; Fierlbeck G; Röcken M
    Br J Dermatol; 2008 Apr; 158(4):867-9. PubMed ID: 18284393
    [No Abstract]   [Full Text] [Related]  

  • 59. Effective management of psoriasis symptom worsening during efalizumab therapy without discontinuing treatment: a case study.
    Gisondi P; Giglio MD; Girolomoni G
    J Dermatolog Treat; 2006; 17(3):172-5. PubMed ID: 16854760
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis.
    Leonardi CL; Toth D; Cather JC; Langley RG; Werther W; Compton P; Kwon P; Wetherill G; Curtin F; Menter A
    Dermatology; 2006; 213(3):204-14. PubMed ID: 17033169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.